Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Download Data

Immix Biopharma Inc Inventory Turnover Ratio for the quarter ending March 31, 2024: 23,850.00

Immix Biopharma Inc Inventory Turnover Ratio is 23,850.00 for the quarter ending March 31, 2024. The inventory turnover ratio measures the efficiency of a company's inventory management by assessing how quickly it sells and replaces its inventory. It is calculated by dividing the cost of revenue by the average inventory value. This ratio indicates the number of times the company's inventory is sold and replaced within a specific period. A higher turnover ratio suggests efficient inventory management, while a lower ratio may indicate slow sales or excess inventory.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends